PRAME and acute leukemia: To date, WT1, BIRC5, and PRAME have not been promoted as biomarkers of relapse, likely in part due to the scant data for BIRC5 and PRAME and the lack of sensitivity for detection of relapse in prior studies of WT1 in acute leukemia (3, 53).